Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Semaglutide | Tesofensine | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily. | Research indicates 0.25-0.5 mg daily via oral administration. |
| Timing | SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications. | Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia. |
| Cycle Duration | Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials). | 12-24 week cycles. Monitor cardiovascular parameters throughout. |
| Evidence Level | Strong (FDA-approved) | moderate_human |
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.
Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor with affinity for dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters. It suppresses appetite through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, reflecting additive effects of increased NE and DA activity. Tesofensine is a dual-action drug with both anorexigenic properties (appetite suppression) and metabolic properties (increased energy expenditure), silencing GABAergic hypothalamic neurons in the lateral hypothalamus.
Research indicates 0.25-0.5 mg daily via oral administration.
Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia.
12-24 week cycles. Monitor cardiovascular parameters throughout.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →